Skip to main content
SpringerLink
Log in

Ameliorative effects of Nigella sativa on dyslipidemia

  • Review
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

Introduction

Dyslipidemia is an established risk factor for ischemic heart disease. Nigella sativa (NS) is a medicinal plant that has been used for the treatment and prevention of a variety of diseases, in particular hyperlipidemia.

Methods

We reviewed the existing literature published until 2014 by using the following keywords: ‘‘Nigella sativa’’, ‘‘black cumin’’, ‘‘black seeds’’, ‘‘thymoquinone’’, and ‘‘lipid’’.

Results

In the conducted studies, different preparations of NS including seed powder (100 mg–20 g daily), seed oil (20–800 mg daily), thymoquinone (3.5–20 mg daily), and seed extract (methanolic extract especially), were shown to reduce plasma levels of total cholesterol, low-density lipoprotein cholesterol (LDL-C) and triglycerides, but the effect on high-density lipoprotein cholesterol (HDL-C) was not significant. NS and thymoquinone have been reported to be safe and well tolerated with no severe adverse effect. In clinical trials, NS was found to be effective when added as adjunct to standard antihyperlipidemic and antidiabetic medications. Lipid-modifying effects of NS could be attributed to the inhibition of intestinal cholesterol absorption, decreased hepatic cholesterol synthesis, and up-regulation of LDL receptors.

Conclusions

Overall, the evidence from experimental and a clinical studies suggests that NS seeds are a promising natural therapy for dyslipidemic patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Peterson AL, McBride PE (2012) A review of guidelines for dyslipidemia in children and adolescents. Age 20:8

    Google Scholar 

  2. Miller M (2003) Niacin as a component of combination therapy for dyslipidemia. In: Mayo Clinic Proceedings. Elsevier

  3. Wietlisbach V et al (1997) Trends in cardiovascular risk factors (1984–1993) in a Swiss region: results of three population surveys. Prev Med 26(4):523–533

    Article  CAS  PubMed  Google Scholar 

  4. Cannon CP et al (2006) Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol 48(3):438–445

    Article  CAS  PubMed  Google Scholar 

  5. Fruchart J-C et al (2008) The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol 102(10):1K–34K

    Article  PubMed  Google Scholar 

  6. Hermans MP et al (2009) Centralized Pan-European survey on the under-treatment of hypercholesterolaemia (CEPHEUS): overall findings from eight countries. Curr Med Res Opin 26(2):445–454

    Article  Google Scholar 

  7. Leiter L et al (2011) Persistent lipid abnormalities in statin-treated patients with diabetes mellitus in Europe and Canada: results of the Dyslipidaemia International Study. Diabet Med 28(11):1343–1351

    Article  CAS  PubMed  Google Scholar 

  8. Norata GD, Ballantyne CM, Catapano AL (2013) New therapeutic principles in dyslipidaemia: focus on LDL and Lp (a) lowering drugs. Eur Heart J 34(24):1783–1789

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  9. Sahebkar A, Chew GT, Watts GF (2014) Recent advances in pharmacotherapy for hypertriglyceridemia. Prog Lipid Res 56:47–66

    Article  CAS  PubMed  Google Scholar 

  10. Hasani-Ranjbar S, Larijani B, Abdollahi M (2009) A systematic review of the potential herbal sources of future drugs effective in oxidant-related diseases. Inflamm Allerg Drug Target Former Curr Drug Target Inflamm Allerg 8(1):2–10

    Article  CAS  Google Scholar 

  11. Kocyigit Y, Atamer Y, Uysal E (2009) The effect of dietary supplementation of Nigella sativa L. on serum lipid profile in rats. Saudi Med J 30(7):893–896

    PubMed  Google Scholar 

  12. Muhammad TS (2009) Characterization of black cumin seed oil and exploring its role as a functional food. University of Agriculture, Faisalabad

    Google Scholar 

  13. Shuid AN, et al. (2012) Nigella sativa: a potential antiosteoporotic agent. Evid Based Complement Altern Med

  14. Datau E et al (2010) Efficacy of Nigella sativa on serum free testosterone and metabolic disturbances in central obese male. Acta Med Indones 42(3):130–134

    CAS  PubMed  Google Scholar 

  15. Ramadan MF (2007) Nutritional value, functional properties and nutraceutical applications of black cumin (Nigella sativa L.): an overview. Int J Food Sci Technol 42(10):1208–1218

    Article  CAS  Google Scholar 

  16. Babayan V, Koottungal D, Halaby G (1978) Proximate analysis, fatty acid and amino acid composition of Nigella sativa L. seeds. J Food Sci 43(4):1314–1315

    Article  CAS  Google Scholar 

  17. Üstun G et al (1990) Investigation of the technological properties of Nigella sativa (black cumin) seed oil. J Am Oil Chem Soc 67(12):958–960

    Article  Google Scholar 

  18. Hosseinzadeh H et al (2013) Effect of aqueous and ethanolic Extracts of Nigella sativa seeds on milk production in rats. J Acupunct Meridian Stud 6(1):18–23

    Article  PubMed  Google Scholar 

  19. Ahmad S, Beg ZH (2013) Elucidation of mechanisms of actions of thymoquinone-enriched methanolic and volatile oil extracts from Nigella sativa against cardiovascular risk parameters in experimental hyperlipidemia. Lipids Health Dis 12(1):86

    Article  PubMed Central  PubMed  Google Scholar 

  20. Shabana A et al (2013) Cardiovascular benefits of black cumin (Nigella sativa). Cardiovasc Toxicol 13(1):9–21

    Article  PubMed  Google Scholar 

  21. Mannan A, Kahvic M (2010) Ibn Sina: a tribute. Gulf J Oncol 7:60–63

    Google Scholar 

  22. Ali B, Blunden G (2003) Pharmacological and toxicological properties of Nigella sativa. Phytother Res 17(4):299–305

    Article  CAS  PubMed  Google Scholar 

  23. Salem ML (2005) Immunomodulatory and therapeutic properties of the Nigella sativa L. seed. Int Immunopharmacol 5(13):1749–1770

    Article  CAS  PubMed  Google Scholar 

  24. Amarouch H et al (2002) Effects of Nigella sativa fixed oil on blood homeostasis in rat. J Ethnopharmacol 79(1):23–26

    Article  PubMed  Google Scholar 

  25. Nickavar B et al (2003) Chemical composition of the fixed and volatile oils of Nigella sativa L. from Iran. Zeitschrift Fur Naturforschung C 58(9/10):629–631

    CAS  Google Scholar 

  26. Dicke M, Van Loon JJ, Soler R (2009) Chemical complexity of volatiles from plants induced by multiple attack. Nat Chem Biol 5(5):317–324

    Article  CAS  PubMed  Google Scholar 

  27. Mansour M et al (2001) Effects of the volatile oil constituents of Nigella sativa on carbon tetrachloride induced hepatotoxicity in mice: evidence for antioxidant effects of thymoquinone. Res Commun Mol Pathol Pharmacol 110(3–4):239–251

    CAS  PubMed  Google Scholar 

  28. Salama RHM (2011) Hypoglycemic effect of lipoic acid, carnitine and Nigella sativa in diabetic rat model. Int J Health Sci 5(2):126

    CAS  Google Scholar 

  29. Kanter M, Akpolat M, Aktas C (2009) Protective effects of the volatile oil of Nigella sativa seeds on β-cell damage in streptozotocin-induced diabetic rats: a light and electron microscopic study. J Mol Histol 40(5–6):379–385

    Article  CAS  PubMed  Google Scholar 

  30. Shafiee-Nick R, et al. (2012) Chronic administration of a combination of six herbs inhibits the progression of hyperglycemia and decreases serum lipids and aspartate amino transferase activity in diabetic rats. Adv Pharmacol Sci 2012

  31. Meral I et al (2001) Effect of Nigella sativa on glucose concentration, lipid peroxidation, anti-oxidant defence system and liver damage in experimentally-induced diabetic rabbits. J Vet Med Ser A 48(10):593–599

    Article  CAS  Google Scholar 

  32. Dehkordi FR, Kamkhah AF (2008) Antihypertensive effect of Nigella sativa seed extract in patients with mild hypertension. Fundam Clin Pharmacol 22(4):447–452

    Article  CAS  PubMed  Google Scholar 

  33. Ghannadi A, Hajhashemi V, Jafarabadi H (2005) An investigation of the analgesic and anti-inflammatory effects of Nigella sativa seed polyphenols. J Med Food 8(4):488–493

    Article  CAS  PubMed  Google Scholar 

  34. Alemi M et al (2013) Anti-inflammatory effect of seeds and callus of Nigella sativa L. extracts on mix glial cells with regard to their thymoquinone content. AAPS Pharm Sci Tech 14(1):160–167

    Article  CAS  Google Scholar 

  35. Abdel-Wahhab M, Aly S (2005) Antioxidant property of Nigella sativa (black cumin) and Syzygium aromaticum (clove) in rats during aflatoxicosis. J Appl Toxicol 25(3):218–223

    Article  CAS  PubMed  Google Scholar 

  36. Burits M, Bucar F (2000) Antioxidant activity of Nigella sativa essential oil. Phytother Res 14(5):323–328

    Article  CAS  PubMed  Google Scholar 

  37. Randhawa MA, Alghamdi MS (2011) Anticancer activity of Nigella sativa (black seed)—a review. Am J Chin Med 39(06):1075–1091

    Article  CAS  PubMed  Google Scholar 

  38. Ezz HSA, Khadrawy YA, Noor NA (2011) The neuroprotective effect of curcumin and Nigella sativa oil against oxidative stress in the pilocarpine model of epilepsy: a comparison with valproate. Neurochem Res 36(11):2195–2204

    Article  PubMed  Google Scholar 

  39. Abdel-Sater KA (2009) Gastroprotective effects of Nigella Sativa oil on the formation of stress gastritis in hypothyroidal rats. Int J Physiol Pathophysiol Pharmacol 1(2):143

    PubMed Central  PubMed  Google Scholar 

  40. Bakathir HA, Abbas NA (2011) Detection of the antibacterial effect of Nigella sativa ground seeds with water. Afr J Tradit Complement Altern Med 8(2)

  41. Khan M et al (2003) The in vivo antifungal activity of the aqueous extract from Nigella sativa seeds. Phytother Res 17(2):183–186

    Article  CAS  PubMed  Google Scholar 

  42. Coban S et al (2010) The effects of Nigella sativa on bile duct ligation induced-liver injury in rats. Cell Biochem Funct 28(1):83–88

    Article  CAS  PubMed  Google Scholar 

  43. Sultan MT, et al. (2014) Nigella sativa fixed and essential oil supplementation modulates hyperglycemia and allied complications in streptozotocin-induced diabetes mellitus. Evid Based Complement Altern Med

  44. Kaleem M et al (2006) Biochemical effects of Nigella sativa L seeds in diabetic rats. Ind J Exp Biol 44(9):745

    CAS  Google Scholar 

  45. Ikram F, Hussain F (2014) Antidiabetic Efficacy of Nigella sativa Linn. in Alloxan-induced Diabetic Rabbits. Int Med J Malays 13(1)

  46. Ghorbani A et al (2013) Antihyperlipidemic effect of a polyherbal mixture in streptozotocin-induced diabetic rats. J Lipids

  47. VM Suriyavathana, Krishnan N (2011) Ayurvedic formulation of Liv-Pro-08 reduces nonalcoholic fatty liver disease in rats fed with high-fat diet. J Acupunct Meridian Studies 4(4):236–241

    Article  Google Scholar 

  48. Nader MA, El-Agamy DS, Suddek GM (2010) Protective effects of propolis and thymoquinone on development of atherosclerosis in cholesterol-fed rabbits. Arch Pharmacal Res 33(4):637–643

    Article  CAS  Google Scholar 

  49. Ahmad S, Beg ZH (2013) Hypolipidemic and antioxidant activities of thymoquinone and limonene in atherogenic suspension fed rats. Food Chem 138(2):1116–1124

    Article  CAS  PubMed  Google Scholar 

  50. Ragheb A et al. (2008) Attenuation of the development of hypercholesterolemic atherosclerosis by thymoquinone. Int J Angiol Off Pub Int College Angiol Inc 17(4): 186

  51. Asgary S et al (2013) Nigella sativa L. improves lipid profile and prevents atherosclerosis: evidence from an experimental study on hypercholesterolemic rabbits. J Funct Foods 5(1):228–234

    Article  CAS  Google Scholar 

  52. Palodhi S, Dutta S (2010) Effect of atorvastatin and black seed (Nigella Sativa) in experimentally induced hypercholesterolemia in rabbits Suhrita Paul Kalyan Kumar Paul 2

  53. Ebrahimzadeh Attari V et al (2010) The effect of powdered form of nigella sativa on serum lipid profile, body weight and intake food in hyperlipidemic rabbit. Med Uni Zanjan 18(70): 31–43

  54. El-Dakhakhny M, Mady NI, Halim MA (2000) Nigella sativa L. oil protects against induced hepatotoxicity and improves serum lipid profile in rats. Arzneimittelforschung 50(09):832–836

    CAS  PubMed  Google Scholar 

  55. Al-Rasheed N et al (2014) Potential protective effects of Nigella sativa and Allium sativum against fructose-induced metabolic syndrome in rats. J Oleo Sci 63:839–848

    Article  CAS  PubMed  Google Scholar 

  56. Parhizkar S et al (2011) Preventive effect of Nigella sativa on metabolic syndrome in menopause induced rats. J Med Plants Res 5(8):1478–1484

    Google Scholar 

  57. Parhizkar S, et al. (2011) Metabolic impact of Nigella sativa extracts on experimental menopause induced rats

  58. Al-Nazawi M, El-Bahr S (2012) Hypolipidemic and hypocholestrolemic effect of medicinal plant combination in the diet of rats: black cumin seed. J Animal Vet Adv 11(12):2013–2019

    Article  CAS  Google Scholar 

  59. Charlton M (2009) Obesity, hyperlipidemia, and metabolic syndrome. Liver Transpl 15(S2):S83–S89

    Article  PubMed  Google Scholar 

  60. Farzaneh E et al (2014) The effects of 8-week Nigella sativa supplementation and aerobic training on lipid profile and VO2 max in sedentary overweight females. Int J Prevent Med 5(2):210

    Google Scholar 

  61. Sabzghabaee AM et al (2011) Clinical evaluation of Nigella sativa seeds for the treatment of hyperlipidemia: a randomized, placebo controlled clinical trial. Med Arh 66(3):198–200

    Article  Google Scholar 

  62. Hamed AAA (2014) Effect of Nigella sativa and Allium sativum coadminstered with simvastatin in dyslipidemia patients: a prospective randomized double-blind trial. Anti Inflamm Anti Allerg Agents Med Chem Former Curr Med Chem Anti Inflamm Anti Allerg Agents 13(1):68–74

    Google Scholar 

  63. Ibrahim RM et al (2014) Protective effects of Nigella sativa on metabolic syndrome in menopausal women. Adv Pharm Bull 4(1):29

    PubMed Central  PubMed  Google Scholar 

  64. Najmi A et al (2008) Effect of Nigella sativa oil on various clinical and biochemical parameters of insulin resistance syndrome. Int J Diabet Dev Ctries 28(1):11

    Article  Google Scholar 

  65. Bamosa A (2014) Nigella sativa is a safe herbal product. J Integr Med 12(1):66

    Article  PubMed  Google Scholar 

  66. Randhawa MA (2008) Black seed, Nigella sativa, deserves more attention. J Ayub Med Coll Abbottabad 20(2):1–2

    PubMed  Google Scholar 

  67. Vahdati-Mashhadian N, Rakhshandeh H, Omidi A (2005) An investigation on LD50 and subacute hepatic toxicity of Nigella sativa seed extracts in mice. Die Pharm Int J Pharm Sci 60(7):544–547

    CAS  Google Scholar 

  68. Amarouch H, et al. (2002) Acute and chronic toxicity of Nigella sativa fixed oil

  69. Al-Amri AM, Bamosa AO (2009) Phase I safety and clinical activity study of thymoquinone in patients with advanced refractory malignant disease. Shiraz E Med J 10:107–111

    Google Scholar 

  70. Al-Naqeeb G, Ismail M (2009) Regulation of apolipoprotein A-1 and apolipoprotein B100 genes by thymoquinone rich fraction and thymoquinone in HEPG2 cells. J Food Lipids 16(2):245–258

    Article  CAS  Google Scholar 

  71. Mariod AA et al (2009) Antioxidant activity and phenolic content of phenolic rich fractions obtained from black cumin (Nigella sativa) seedcake. Food Chem 116(1):306–312

    Article  CAS  Google Scholar 

  72. Badary OA et al (2003) Thymoquinone is a potent superoxide anion scavenger. Drug Chem Toxicol 26(2):87–98

    Article  CAS  PubMed  Google Scholar 

  73. Meyer AS et al (1997) Inhibition of human low-density lipoprotein oxidation in relation to composition of phenolic antioxidants in grapes (Vitis vinifera). J Agric Food Chem 45(5):1638–1643

    Article  CAS  Google Scholar 

  74. Vinson JA, Teufel K, Wu N (2004) Green and black teas inhibit atherosclerosis by lipid, antioxidant, and fibrinolytic mechanisms. J Agric Food Chem 52(11):3661–3665

    Article  CAS  PubMed  Google Scholar 

  75. Eder K et al (2002) Excess dietary vitamin E lowers the activities of antioxidative enzymes in erythrocytes of rats fed salmon oil. The Journal of nutrition 132(11):3400–3404

    CAS  PubMed  Google Scholar 

  76. Bamosa AO, Ali B, Sowayan S (1997) Effect of oral ingestion Nigella sativa seeds on some blood parameters. Saudi Pharmaceutical Journal 5:126–129

    Google Scholar 

  77. Brufau G, Canela MA, Rafecas M (2008) Phytosterols: physiologic and metabolic aspects related to cholesterol-lowering properties. Nutr Res 28(4):217–225

    Article  CAS  PubMed  Google Scholar 

  78. Bitzur R (2013) Phytosterols: another way to reduce LDL cholesterol levels. Vasc Dis J, p 25

  79. Jones PJ et al (2003) Phytosterols in low-and nonfat beverages as part of a controlled diet fail to lower plasma lipid levels. J Lipid Res 44(9):1713–1719

    Article  CAS  PubMed  Google Scholar 

  80. Al-Naqeep G, Ismail M, Allaudin Z (2009) Regulation of low-density lipoprotein receptor and 3-hydroxy-3-methylglutaryl coenzyme A reductase gene expression by thymoquinone-rich fraction and thymoquinone in HepG2 cells. J Nutr Nutrigenom 2(4–5):163–172

    Article  CAS  Google Scholar 

  81. Pourghassem-Gargari B et al (2009) Effect of dietary supplementation with Nigella sativa L. on serum lipid profile, lipid peroxidation and antioxidant defense system in hyperlipidemic rabbits. J Med Plants Res 3(10):815–821

    CAS  Google Scholar 

  82. Kota SK et al (2013) Implications of serum paraoxonase activity in obesity, diabetes mellitus, and dyslipidemia. Ind J Endocrinol Metab 17(3):402

    Article  CAS  Google Scholar 

  83. Najmi A et al (2012) Therapeutic effect of nigella sativa in patients of poor glycemic control. Asian J Pharm Clin Res 5:224–228

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Isfahan Cardiovascular Research Institute, Isfahan Cardiovascular Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

    S. Asgary

  2. Biotechnology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

    A. Sahebkar

  3. Isfahan Cardiovascular Research Institute, Isfahan Cardiovascular Research Center, Isfahan University of Medical Sciences, Khorram st., Isfahan, Iran

    N. Goli-malekabadi

Authors
  1. S. Asgary
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Sahebkar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. N. Goli-malekabadi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to N. Goli-malekabadi.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Informed consent

For this type of study formal consent is not required.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Asgary, S., Sahebkar, A. & Goli-malekabadi, N. Ameliorative effects of Nigella sativa on dyslipidemia. J Endocrinol Invest 38, 1039–1046 (2015). https://doi.org/10.1007/s40618-015-0337-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40618-015-0337-0

Keywords

Search

Navigation